Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. حسب Hongliang Chen (538815)

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

"…Their median baseline variabilities of respiratory rate and tidal volume were 0.19 (IQR: 0.16–0.25) and 0.23 (0.19–0.34), respectively. While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …"

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. حسب Florentin Pastor (19852287)

الموضوعات: "…chronically infected patients…"

Word cloud with key elements of an Active Learning Classroom. حسب Mairena Sánchez-López (684092)

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

الموضوعات:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. حسب Erienne G. Norton (9612079)

الموضوعات:

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. حسب Montserrat Llanses Martinez (17797522)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression حسب Julia Cataldo Lima (22811497)

"…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …"

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Clinical course of patient no. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Flowchart of patient selection in this study. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Mean posterior estimates for parameters of interest for each simulated dataset varying across date resolution. حسب Leo A. Featherstone (21078333)

الموضوعات:

Patient characteristics. حسب Young Kyu Lee (14076058)

الموضوعات: